Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib Phase 1 in Japanese R/R AML
NCT02675478Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of subjects experiencing adverse events at 1 year, Cmax of quizartinib and its active metabolite at Cycle 2 and 4 more. Started Feb 2016; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02675478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675478.